Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASIST: BXQ-350 + mFOLFOX7 + Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT05322590Phase 2Active, not recruiting
- Sponsor
- Bexion Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of BXQ-350 in colorectal cancer (CRC), sponsored by Bexion Pharmaceuticals. Started Jan 2023; status: active, not recruiting.
02
Drugs
BXQ-350
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05322590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322590.